The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia a patient with inhibitor
Tourbaf, K.D.; Dunlap, B.E.; Ambrus, J.L.; Rodman, D.J.; Atwal, A.J.
Journal of Medicine 13(5-6): 399-410
1982
ISSN/ISBN: 0025-7850 PMID: 6820380 Document Number: 195647
A 34-year-old patient, with severe factor VIII deficiency (anti-hemophilic factor deficiency) and inhibitor against factor VIII, underwent a phacoemulsification with posterior capsulatomy and thermal iridectomy under general anesthesia. FEIBA (Factor Eight Inhibitor Bypassing Activity) was used to achieve hemostasis. The surgical procedure was successful and no complication was ensued. A brief management of hemophilia A patient requiring surgery is discussed.
Document emailed within 1 workday
Related Documents
Hofmann, V.; Ermanni, M.; Straub, P.W. 1978: Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings) Schweizerische Medizinische Wochenschrift 108(41): 1600Ambriz-Fernández, R.; Reyna-Fregoso, M.P.; Pizzuto-Chávez, J.; Rodríguez-Moyado, H.; Farfán-Canto, J.M.; Trueba-Christy, E.; Collazo-Jaloma, J. 1985: Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. a study of the cooperative group of hemophilia Archivos de Investigacion Medica 16(3): 225-235
Schoppmann, A.; Waytes, A.T. 1996: Factor VIIi inhibitor and severity of hemophilia Thrombosis and Haemostasis 76(2): 280-281
Löfqvist, T.; Petersson, C.; Nilsson, I.M. 1997: Radioactive synoviorthesis in patients with hemophilia with factor inhibitor Clinical Orthopaedics and Related Research 343: 37-41
Pfyffer, M.; Kistler, H.J.; von Felten, A. 1983: Acquired hemophilia a due to factor VIIIC inhibitor: detection of circulating immune complexes containing factor VIIIC but not factor VIIIR Schweizerische Medizinische Wochenschrift 113(40): 1456-1459
Iizuka, A.; Kuwashima, M.; Nagao, T. 1982: Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIIi or IX Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 45(5): 987-992
Scharf, R.; Kucharski, W.; Lopaciuk, S.; Celińska, W.; Dmytrow, A.; Domański, K.; Gonet, S.; Miastkowski, Z.; Nowakowska, I.; Przybylski, A. 1991: Preliminary experience with achieving immune tolerance in patients with hemophilia a and circulating factor VIIi inhibitor Acta Haematologica Polonica 22(1): 92-99
Richard, C.; Sedano, C.; Cuadrado, M.A.; Iriondo, A.; Bello, C.; Gandarillas, M.A.; Zubizarreta, A. 1986: Effect of a thymic factor on the concentration of a factor VIIi inhibitor in a patient with treated Hodgkin's disease Thrombosis and Haemostasis 55(2): 299-300
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Akahori, M.; Yamane, T.; Hino, M.; Ohta, K.; Takubo, T.; Samori, T.; Tatsumi, N. 1999: Non-hemophilic patient with inhibitor against factor VIIi produced after the second delivery Rinsho Byori. Japanese Journal of Clinical Pathology 47(9): 891-895
Laurell, M.; Stenflo, J. 1989: Protein C inhibitor from human plasma: characterization of native and cleaved inhibitor and demonstration of inhibitor complexes with plasma kallikrein Thrombosis and Haemostasis 62(3): 885-891
Caputo, R.P.; Giambartolomei, A.; Simons, A.; Reger, M.; Wagner, S.; Esente, P. 2001: Adjunctive therapies in the cath lab. use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia Journal of Invasive Cardiology 13(9): 657-660
Tham, C.J.; Trew, M.; Brager, N. 1999: Abnormal clotting and production of factor VIIi inhibitor in a patient treated with venlafaxine Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 44(9): 923-924
Joo, K.M.; Song, S.Y.; Park, K.; Kim, M.H.; Jin, J.; Kang, B.G.; Jang, M.J.; Lee, G.S.; Kim, M.S.; Nam, D.-H. 2008: Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors International Journal of Oncology 33(4): 705-712
Primrose, J.N.; Davies, J.A.; Prentice, C.R.; Hughes, R.; Johnston, D. 1992: Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity Thrombosis and Haemostasis 68(4): 396-399
Mukherjee, M.; Ranlall, N.; Patel, G.; Rutlin, A.; Jehanli, A.; Kakkar, V.V. 2000: Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 11(3): 285-291
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Jastrzebska, M.; Przybycień, K.; Chelstowski, K.; Torbus-Lisiecka, B.; Kornacewicz-Jach, Z.; Naruszewicz, M. 1999: Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography Nutrition Metabolism and Cardiovascular Diseases: Nmcd 9(1): 33-40
Goetzl, E.J.; Rocklin, R.E. 1978: Amplification of the activity of human leukocyte inhibitory factor (LIF) by the generation of a low molecular weight inhibitor of PMN leukocyte chemotaxis Journal of Immunology 121(3): 891-896